Study of antitumor efficacy of the peptide inhibitor of Ras-GTpase (Ing-Ras) in a xenograft model of non-small cell lung cancer

In recent years, the problem of treating malignant neoplasms arising due to activation of the RAS oncogene has received increasing attention in cancer therapy. A high proportion of mutations in the RAS gene is characteristic of tumors of various localizations, which makes it an attractive therapeutic target. Modern drugs selectively inhibiting mutant KRAS , against the background of significant advantages compared to traditional methods of treatment, have a number of disadvantages, in particular, a high incidence of side effects. Therefore, the development of new drugs of Ras-GTPase inhibitors with improved pharmacodynamic characteristics is an urgent task. The aim of this work was to study in vivo specific pharmacological activity of a new peptide inhibitor of Ras-GTPase (Ing-Ras) on xenograft model of non-small cell lung cancer. There were statistically significant findings of a 16% increase in longevity in mice compared to controls when the drug was administered at a dose of 5 mg/kg and 36.3% when administered at a dose of 10 mg/kg. A dose-dependent inhibition of tumor growth of 30.5% and 57.3% was also observed, respectively. The high specificity due to the mechanism of action of the peptide construct allows us to expect minimization of side effects of the potential drug Ing-Ras.